Advantages of adjusting the initial dose of intravenous calcitriol according to PTH levels

Kidney International, Supplement

Volumn 63, Issue 85, 2003, Pages

  Rodríguez García, Minerva ^b   Fernández Martín, José Luis ^b   De Castañeda, Jaime Ruiz ^b   Hervás Sánchez, José ^b   Cannata Andía, Jorge Benito ^a  

^a HOSPITAL UNIVERSITARIO CENTRAL DE ASTURIAS   (Spain)

^b NONE

Author keywords

Hemodialysis; Hyperparathyroidism; Parathyroid hormone

Indexed keywords

CALCITRIOL; PARATHYROID HORMONE;

ADULT; AGED; CLINICAL TRIAL; CONFERENCE PAPER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; DOSE RESPONSE; DRUG EFFICACY; HUMAN; HYPERCALCEMIA; HYPERPARATHYROIDISM; HYPERPHOSPHATEMIA; MAJOR CLINICAL STUDY; MULTICENTER STUDY; PARATHYROID HORMONE BLOOD LEVEL; PATIENT COMPLIANCE; PRIORITY JOURNAL; SIDE EFFECT; TREATMENT OUTCOME;

EID: 0037512521     PISSN: 00986577     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1523-1755.63.s85.19.x     Document Type: Conference Paper

References (16)

1. SLATOPOLSKY E, DELMEZ JA: Pathogenesis of secondary hyperparathyroidism. Am J Kidney Dis 23:229-236, 1994
2. BROWN EM, GAMBA G, RICCARDI D, et al: Cloning and characterization of an extracellular Ca(2+)-sensing receptor from bovine parathyroid. Nature 366:575-580, 1993
3. CANNATA JB, WERUAGA A, GÓMEZ C: Osteodistrofia renal: Diagnóstico y tratamiento. Nefrologia 18:81-91, 1998
4. SILVER J: Molecular mechanisms of secondary hyperparathyroidism. Nephrol Dial Transplant 15(Suppl 5):2-7, 2000
5. MARTÍN KJ, GONZÁLEZ EA: Strategies to minimize bone disease in renal failure. Am J Kidney Dis 38:1430-1436, 2001
6. DÍAZ CORTE C, NAVES ML, RODRÍGUEZ A, et al: Centros colaboradores del Estudio Multicéntrico sobre Osteodistrofia renal: Osteodistrofia renal en España. Encuesta multicéntrica (I). Nefrologia 20:234-243, 2000
7. DÍAZ CORTE C, RODRÍGUEZ A, NAVES ML, et al: Centros colaboradores del Estudio Multicéntrico sobre Osteodistrofia renal: Marcadores metabólicos óseos y uso de vitamina D en diálisis. Encuesta multicéntrica (II). Nefrologia 20:244-253, 2000
8. DÍAZ-CORTE C, CANNATA-ANDÍA JB: Management of secondary hyperparathyroidism: The gap between diagnosis and treatment. The Renal Osteodystrophy Multicenter Enquiry. Am J Med Sci 320:107-111, 2000
9. DÍAZ-CORTE C, NAVES DÍAZ ML, GÓMEZ ALONSO C, et al: Prevention, diagnosis and treatment of renal osteodystrophy in Spain. Preliminary results from a multicentre enquiry. Nephrol Dial Transplant 13(Suppl 3):51-56, 1998
10. CANNATA ANDÍA JB, FERNÁNDEZ E, GONZÁLEZ MT, et al: Osteodistrofia renal, in Normas de Actuación Clínica en Nefrología. Tratamiento de la Insuficiencia Renal Crónica, edited by Sociedad Española de Nefrología, Ediciones Harcourt, España S.A, 1999, pp 79-93
11. GALLIENI M, BRANCACCIO D, ANTONUCCI F, et al: Twice versus thrice weekly administration of intravenous calcitriol in dialysis patients: A randomized prospective trial. Gruppo Italiano di Studio dell'Osteodistrofia Renale. Clin Nephrol 53:188-193, 2000
12. SPRAGUE SM, LERMA E, MCCORMMICK D, et al: Suppression of parathyroid hormone secretion in hemodialysis patients: Comparison of paricalcitol with calcitriol. Am J Kidney Dis 38:S51-56, 2001
13. FERNÁNDEZ E, LLACH F: Guidelines for dosing of intravenous calcitriol in dialysis patients with hyperparathyroidism. Nephrol Dial Transplant 11(Suppl 3):96-101, 1996
14. REICHEL H, SZABO A, UHL J, et al: Intermittent versus continuous administration of 1,25-dihydroxyvitamin D3 in experimental renal hyperparathyroidism. Kidney Int 44:1259-1265, 1993
15. LLACH F, HERVÁS J, CEREZO S: The importance of dosing intravenous calcitriol in dialysis patients with severe hyperparathyroidism. Am J Kidney Dis 26:845-851, 1995
16. RODRÍGUEZ GARCÍA M, FERNÁNDEZ MARTIN JL, RUIZ DE CASTAÑEDA J, et al: Grupo de estudio Caldial: Optimización de la dosis de calcitriol en el tratamiento del hiperparatiroidismo secundario en diálisis. Resultados de seis meses. Nefrologia 12:370-376, 2002